REALMS study: real-world effectiveness and safety of fingolimod in patients with relapsing-remitting multiple sclerosis in Portugal.

Sonia BatistaC C NunesJ J CerqueiraAna Martins SilvaJ Correia de SáJ FerreiraM T MendonçaJ PinheiroV SalgadoA S CorreiaJ SequeiraA CostaL Sousa

Published in: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2020)

Therapy with fingolimod showed a sustained effectiveness and safety over the 3 years, particularly on patients switched from first-line drugs (BRACE). No new safety issues were reported.

Keyphrases

multiple sclerosis
white matter
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
prognostic factors
stem cells
rheumatoid arthritis
patient reported